130 related articles for article (PubMed ID: 36395587)
1. Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
Ezzati A; Buse DC; Fanning KM; Reed ML; Martin VT; Lipton RB
Clin Neurol Neurosurg; 2022 Dec; 223():107511. PubMed ID: 36395587
[TBL] [Abstract][Full Text] [Related]
2. Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine.
Ezzati A; Fanning KM; Reed ML; Lipton RB
Headache; 2023 Mar; 63(3):342-352. PubMed ID: 36748728
[TBL] [Abstract][Full Text] [Related]
3. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
[TBL] [Abstract][Full Text] [Related]
4. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
[TBL] [Abstract][Full Text] [Related]
5. Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
Ezzati A; Fanning KM; Buse DC; Pavlovic JM; Armand CE; Reed ML; Martin VT; Lipton RB
Headache; 2022 Jun; 62(6):755-765. PubMed ID: 35546653
[TBL] [Abstract][Full Text] [Related]
6. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
7. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
10. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
11. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
12. Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
Lipton RB; Buse DC; Dodick DW; Schwedt TJ; Singh P; Munjal S; Fanning K; Bostic Bs R; Reed ML
Headache; 2021 Jan; 61(1):103-116. PubMed ID: 33326608
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study.
Hutchinson S; Lipton RB; Ailani J; Reed ML; Fanning KM; Adams AM; Buse DC
Mayo Clin Proc; 2020 Apr; 95(4):709-718. PubMed ID: 32247344
[TBL] [Abstract][Full Text] [Related]
14. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.
Lipton RB; Manack Adams A; Buse DC; Fanning KM; Reed ML
Headache; 2016 Sep; 56(8):1280-9. PubMed ID: 27349336
[TBL] [Abstract][Full Text] [Related]
16. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
17. Risk of medication overuse headache across classes of treatments for acute migraine.
Thorlund K; Sun-Edelstein C; Druyts E; Kanters S; Ebrahim S; Bhambri R; Ramos E; Mills EJ; Lanteri-Minet M; Tepper S
J Headache Pain; 2016 Dec; 17(1):107. PubMed ID: 27882516
[TBL] [Abstract][Full Text] [Related]
18. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
19. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
20. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
Lipton RB; Munjal S; Alam A; Buse DC; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
Headache; 2018 Oct; 58(9):1408-1426. PubMed ID: 30341895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
